Innovative therapeutics

Investors

BioMarin Appoints Robert J. Hombach, Former Baxalta CFO and COO, to Board of Directors
Oct 3, 2017

SAN RAFAEL, Calif., Oct. 3, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Baxalta Chief Financial Officer and Chief Operations Officer, Robert J. Hombach, to its Board of Directors.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

"We are thrilled to have Bob join BioMarin's Board of Directors.  He brings additional expertise in financial and operational management in the biopharmaceutical industry to an already outstanding board," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer at BioMarin.  "I am confident he will make meaningful contributions to support BioMarin's growth as we continue to develop pioneering therapies for patients with rare genetic diseases."

"I am honored to serve on the board of a company with a 20-year history of developing therapies that make a big difference for small patient populations," said Robert J. Hombach.  "I am looking forward to working with BioMarin as it continues to build its current business, while advancing a robust pipeline during a time of exceptional growth."

About Mr. Hombach

Robert J. Hombach served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta, a biopharmaceutical company spun out from Baxter International in June 2015, until it was acquired by Shire PLC in June 2016. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. From 2007 to 2011, Mr. Hombach also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter.

Mr. Hombach currently serves on the Board of BCU, a national not-for-profit credit union, as chair of the Supervisory Committee.  Previously, he served on the Board of Naurex, Inc., a private pharmaceuticals company acquired by Allergan in 2015, and was a member of the Audit, Compensation, and Transaction Committees.  Mr.Hombach earned an MBA from Northwestern University's JL Kellogg Graduate School of Management, and a BS in Finance cum Laude from the University of Colorado.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin® is a registered trademarks of BioMarin Pharmaceutical Inc.

Contacts:




Investors 

Media

Traci McCarty 

Debra Charlesworth

BioMarin Pharmaceutical Inc. 

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451

 

SOURCE BioMarin Pharmaceutical Inc.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information